General Updates

Date: August 26, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Sub.: Outcome of Board Meeting of the Company held on Wednesday, August 26, 2026 Dear Sir/Madam, With reference to the captioned subject, we wish to inform you that the Board of Directors of the Company at their Meeting held today i.e., Wednesday, August 26, 2026, has inter-alia, approved the following: 1. Appointment of Company Secretary and Compliance Of(cid:976)icer of the Company Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mrs. Shilpa Sharma, an Associate Member of the Institute of Company Secretaries of India (Membership No.: A34516), as the Company Secretary and Compliance Of(cid:976)icer (Key Managerial Personnel) of the Company w.e.f. August 26, 2026. The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the Annexure- A. 2. Appointment of Mr. Viranchi Arvindbhai Shah (DIN: 01598001) as the Non-Executive Additional Director (Independent Director) of the Company Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr. Viranchi Arvindbhai Shah (DIN: 01598001) as an Additional (Non- Executive Independent) Director of the Company, not liable to retire by rotation w.e.f. August 26, 2026 and shall hold shall hold of(cid:976)ice till the ensuing Annual General Meeting of the Company. The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the Annexure- B. Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 3. Authority to determine materiality of an event or information and disclosure to Stock Exchanges In terms of Regulation 30(5) and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the following Key Managerial Personnel have been appointed by the Board of Directors as the authorized officers of the Company to determine materiality of an event or information and for making disclosures thereof: Name Designation Contact Details Authorizations Registered Office: 1101 to 1103, 11th Mr. Swapnil Managing floor, South Tower, Jatinbhai Shah Director ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, To determine materiality of an Ahmedabad, event or information and for Gujarat, India, making disclosures to stock 380054 Whole Time exchange(s). Mr. Deval Director and Tel.: +91-79- Rajnikant Shah Chief Financial 29999857 Officer (CFO) mail: cs@senoresp harma.com Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Company Ahmedabad, To make disclosures of an Mrs. Shilpa Secretary and Gujarat, India, event or information to stock Sharma Compliance 380054 exchange(s). Officer Tel.: +91-79- 29999857 mail: cs@senoresp harma.com 4. Approval of Senores Pharmaceuticals Employee Stock Option Scheme 2026 (“ESOS 2026”/” SCHEME”) Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026 (“ESOS 2026”/”SCHEME”) in accordance with the provisions of the Companies Act, 2013 and the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, subject to the approval of the shareholders of the Company and such other regulatory/statutory approvals as may be necessary. Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the Annexure- 5. Proposed incorporation of a Wholly Owned Subsidiary (WOS) in Mexico The Board of Directors have accorded their approval for incorporation of a Wholly-Owned Subsidiary (WOS) in Mexico to support the Company’s business and strategic objectives in the Mexican and other international markets. The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the Annexure- 6. Proposed incorporation of a Subsidiary Company in Canada The Board of Directors have accorded their approval for incorporation of a Subsidiary Company in Canada to support the Company’s business and strategic objectives in the Canadian and other international markets. The investment in the proposed entity shall either be directly or through its Wholly Owned Subsidiary as per the Canadian applicable law. The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the Annexure- Kindly note that the meeting of Board of Directors of the Company commenced at 04:45 P.M. (IST) and concluded at 05:15 P.M. (IST). This intimation and aforesaid information are also being uploaded on the Company’s website at www.senorespharma.com. You are requested to take the same on record. Thanking you. For Senores Pharmaceuticals Limited Shilpa Sharma Company Secretary & Compliance Officer M.No.: A34516 Enclosures: As above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Annexure-A Appointment of Company Secretary and Compliance Officer of the Company Sr. Particulars Details 1. Reason for change viz. appointment, Appointment of Mrs. Shilpa Sharma (Membership re-appointment, resignation, removal, No.: A34516) as the Company Secretary and death or otherwise Compliance Officer (Key Managerial Personnel) of the Company w.e.f. August 26, 2026. 2. Date of appointment/re- August 26, 2026 appointment/cessation (as applicable) and term of appointment 3. Brief Profile (in case of appointment) Mrs. Shilpa Sharma is a qualified Associate Member of the Institute of Company Secretaries of India (ICSI) and holds a Bachelor’s degree in Law and Commerce from the University of Rajasthan. She brings over 13 years of extensive experience in the corporate sector, including more than 10 years of experience with BSE- and NSE-listed companies. Over the course of her career, Shilpa has developed strong expertise in corporate governance, securities law, listed-company compliances, and complex corporate actions. She has played a key role in several significant transacti [Showing first 8,000 characters — download PDF for full document]